Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 21 Maj | 05:04:12 Europe / Stockholm

Svenska | English

BioStock

Prenumeration

Annexin summarizes Q1: promising study data and fully subscribed issue

2025-05-19 09:43:00

Annexin Pharmaceuticals has entered 2025 with clear progress on two fronts – clinical development and financing. The final analysis from the Phase IIa study in retinal vein occlusion confirms the potential of the drug candidate, with positive efficacy signals and a favorable safety profile, while a recently completed rights issue provides resources to accelerate development.

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden